## PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (571)-273-2885

INSTRUCTIONS. This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the comment correspondence addess as included unless corrected before or directed otherwise in Block 1, by (3) possibles; no new correspondence patents, and/or (b) indenting a temperat-TEE ADDRESS for

44002 7590 03/11/2008 ASTRAZENECA R&D BOSTON 35 GATEHOUSE DRIVE WALTHAM, MA 02451-1215

Note: A contificate of mailing can only be used for domestic mailings of the Foc(s) Transmittal. This continued cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Feed's Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USFTO (71) 273-2885, on the date indicated below.

(Depositor's name Signature (Dat

CONFIRMATION NO APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 10/539,481 06/17/2005 Andrew Austen Mortlock 100937-1P US 2446

TITLE OF INVENTION: QUINAZOLINE COMPOUNDS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1440	\$300	\$0	\$1740	06/11/2008
EXA	MINER	ART UNIT	CLASS-SUBCLASS	1		
TRUONG, TA	AMTHOM NGO	1624	514-080000	•		
R 1.363).  Change of corres Address form PTO/S	dication (or "Fee Address 02 or more recent) attach	inge of Correspondence	(2) the name of a single registered attorney or a	3 registered patent attorn vely, e firm (having as a memb agent) and the names of u meys or agents. If no nam	or a 2	

PLEASE NOTE: Unless an assignce is identified below, no assignee data will appear on the patent. If an recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

AstraZeneca AB

SE-15185 Södertalje, Sweden

Please check the appropriate assignee category or categories (will not be printed on the patent): 🔲 Individual 🖸 Corporation or other private group entity 🚨 Government

4a. The following fee(s) are submitted:	4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)
☐ Issue Fee	A chock is enclosed.
Publication Fee (No small entity discount permitted)	Payment by credit card. Form PTO-2038 is attached.
Advance Order - # of Copies3	The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number 50-3231 (enclose an extra copy of this for
	overpayment, to Deposit Account Number 5(1-3231 (enclose an extra copy of this for
5. Change in Entity Status (from status indicated above)	
a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.	□ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

NOTE: The Issue Foe and Publication Fee (if required) will not be accepted from suryone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

/Theresa Devlin/ Date June 10, 2008 Authorized Signature

Theresa Devlin Registration No. \_\_45,361 Typed or printed name

This collection of information is required by 77 CFR 1.311. The information is required to obtain or train a benuit by the public which is to file (end by the USPTO to process) are application. Confidentially in government 3/5 11.5C 11.2 and 3/5 CFR.1.61 This confidentially in government 3/5 11.5C 11.2 and 3/5 CFR.1.61 This confidential is the completed application from to the USPTO. Then will very depending upon the information of the Confidential Confide

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.